Bioavailability and disposition kinetics of HI-6 in beagle dogs

J. D. Baggot, Alan R Buckpitt, D. Johnson, P. Brennan, H. Chung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The absorption and disposition kinetics of HI-6 were determined in Beagle dogs given single doses (25 mg kg-1) of the drug by the intravenous, intramuscular, and oral routes. Concentrations of the oxime in plasma and urine were measured by HPLC. A two-compartment open model was used to describe the disposition curve following intravenous drug administration while a one-compartment open model with first-order absorption adequately described the data following intramuscular or oral administration of the dose. Extravascular distribution of HI-6 was limited (V(ss)) 203 ml kg-1) and the drug was eliminated rapidly after intravenous administration (t(1/2) 46.5 min, MAT 55.4 min). Systemic clearance was 3.68 ml min-1 x kg. A major fraction of the dose (63.7 per cent) was excreted in urine over a 24-h collection period. Following intramuscular drug administration, the absorption half-life (t(1/2(a)), 5.3 min), MAT (17.1 min), C(max) (70.37 μg ml-1) and t(max) (15.9 min) indicate that the drug was rapidly absorbed. Systemic availability was 83.43 per cent after oral drug administration, absorption was preceded by a lag time (23.2 min). The t(1/2(a)) (41.5 min), MAT (81.6 min), C(max) (4.30 μg ml-1) and T(max) (90.6 min) indicate somewhat delayed absorption. Systemic availability (11.38 per cent) and the fraction of dose excreted unchanged in the urine (9.3 per cent) show that the drug was poorly absorbed. The apparent half-life (58.0 min) and MRT (137.6 min) following oral administration were significantly longer (p < 0.05) than following intravenous or intramuscular suggesting that the rate of absorption from the gastrointestinal tract decreases the elimination rate of the drug. In conclusion, HI-6 has limited distribution within the body, is rapidly eliminated mainly by renal excretion unchanged in the urine, and the bioavailability (i.e. rate and extent of absorption) of the drug varies with the route of administration.

Original languageEnglish (US)
Pages (from-to)93-105
Number of pages13
JournalBiopharmaceutics and Drug Disposition
Volume14
Issue number2
StatePublished - 1993

Fingerprint

Biological Availability
Dogs
Pharmaceutical Preparations
Urine
Oral Administration
Intravenous Administration
Half-Life
Oximes
asoxime chloride
Gastrointestinal Tract
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Baggot, J. D., Buckpitt, A. R., Johnson, D., Brennan, P., & Chung, H. (1993). Bioavailability and disposition kinetics of HI-6 in beagle dogs. Biopharmaceutics and Drug Disposition, 14(2), 93-105.

Bioavailability and disposition kinetics of HI-6 in beagle dogs. / Baggot, J. D.; Buckpitt, Alan R; Johnson, D.; Brennan, P.; Chung, H.

In: Biopharmaceutics and Drug Disposition, Vol. 14, No. 2, 1993, p. 93-105.

Research output: Contribution to journalArticle

Baggot, JD, Buckpitt, AR, Johnson, D, Brennan, P & Chung, H 1993, 'Bioavailability and disposition kinetics of HI-6 in beagle dogs', Biopharmaceutics and Drug Disposition, vol. 14, no. 2, pp. 93-105.
Baggot, J. D. ; Buckpitt, Alan R ; Johnson, D. ; Brennan, P. ; Chung, H. / Bioavailability and disposition kinetics of HI-6 in beagle dogs. In: Biopharmaceutics and Drug Disposition. 1993 ; Vol. 14, No. 2. pp. 93-105.
@article{cb9df6ea7c5a477e8128a6f9d16a4f70,
title = "Bioavailability and disposition kinetics of HI-6 in beagle dogs",
abstract = "The absorption and disposition kinetics of HI-6 were determined in Beagle dogs given single doses (25 mg kg-1) of the drug by the intravenous, intramuscular, and oral routes. Concentrations of the oxime in plasma and urine were measured by HPLC. A two-compartment open model was used to describe the disposition curve following intravenous drug administration while a one-compartment open model with first-order absorption adequately described the data following intramuscular or oral administration of the dose. Extravascular distribution of HI-6 was limited (V(ss)) 203 ml kg-1) and the drug was eliminated rapidly after intravenous administration (t(1/2) 46.5 min, MAT 55.4 min). Systemic clearance was 3.68 ml min-1 x kg. A major fraction of the dose (63.7 per cent) was excreted in urine over a 24-h collection period. Following intramuscular drug administration, the absorption half-life (t(1/2(a)), 5.3 min), MAT (17.1 min), C(max) (70.37 μg ml-1) and t(max) (15.9 min) indicate that the drug was rapidly absorbed. Systemic availability was 83.43 per cent after oral drug administration, absorption was preceded by a lag time (23.2 min). The t(1/2(a)) (41.5 min), MAT (81.6 min), C(max) (4.30 μg ml-1) and T(max) (90.6 min) indicate somewhat delayed absorption. Systemic availability (11.38 per cent) and the fraction of dose excreted unchanged in the urine (9.3 per cent) show that the drug was poorly absorbed. The apparent half-life (58.0 min) and MRT (137.6 min) following oral administration were significantly longer (p < 0.05) than following intravenous or intramuscular suggesting that the rate of absorption from the gastrointestinal tract decreases the elimination rate of the drug. In conclusion, HI-6 has limited distribution within the body, is rapidly eliminated mainly by renal excretion unchanged in the urine, and the bioavailability (i.e. rate and extent of absorption) of the drug varies with the route of administration.",
author = "Baggot, {J. D.} and Buckpitt, {Alan R} and D. Johnson and P. Brennan and H. Chung",
year = "1993",
language = "English (US)",
volume = "14",
pages = "93--105",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Bioavailability and disposition kinetics of HI-6 in beagle dogs

AU - Baggot, J. D.

AU - Buckpitt, Alan R

AU - Johnson, D.

AU - Brennan, P.

AU - Chung, H.

PY - 1993

Y1 - 1993

N2 - The absorption and disposition kinetics of HI-6 were determined in Beagle dogs given single doses (25 mg kg-1) of the drug by the intravenous, intramuscular, and oral routes. Concentrations of the oxime in plasma and urine were measured by HPLC. A two-compartment open model was used to describe the disposition curve following intravenous drug administration while a one-compartment open model with first-order absorption adequately described the data following intramuscular or oral administration of the dose. Extravascular distribution of HI-6 was limited (V(ss)) 203 ml kg-1) and the drug was eliminated rapidly after intravenous administration (t(1/2) 46.5 min, MAT 55.4 min). Systemic clearance was 3.68 ml min-1 x kg. A major fraction of the dose (63.7 per cent) was excreted in urine over a 24-h collection period. Following intramuscular drug administration, the absorption half-life (t(1/2(a)), 5.3 min), MAT (17.1 min), C(max) (70.37 μg ml-1) and t(max) (15.9 min) indicate that the drug was rapidly absorbed. Systemic availability was 83.43 per cent after oral drug administration, absorption was preceded by a lag time (23.2 min). The t(1/2(a)) (41.5 min), MAT (81.6 min), C(max) (4.30 μg ml-1) and T(max) (90.6 min) indicate somewhat delayed absorption. Systemic availability (11.38 per cent) and the fraction of dose excreted unchanged in the urine (9.3 per cent) show that the drug was poorly absorbed. The apparent half-life (58.0 min) and MRT (137.6 min) following oral administration were significantly longer (p < 0.05) than following intravenous or intramuscular suggesting that the rate of absorption from the gastrointestinal tract decreases the elimination rate of the drug. In conclusion, HI-6 has limited distribution within the body, is rapidly eliminated mainly by renal excretion unchanged in the urine, and the bioavailability (i.e. rate and extent of absorption) of the drug varies with the route of administration.

AB - The absorption and disposition kinetics of HI-6 were determined in Beagle dogs given single doses (25 mg kg-1) of the drug by the intravenous, intramuscular, and oral routes. Concentrations of the oxime in plasma and urine were measured by HPLC. A two-compartment open model was used to describe the disposition curve following intravenous drug administration while a one-compartment open model with first-order absorption adequately described the data following intramuscular or oral administration of the dose. Extravascular distribution of HI-6 was limited (V(ss)) 203 ml kg-1) and the drug was eliminated rapidly after intravenous administration (t(1/2) 46.5 min, MAT 55.4 min). Systemic clearance was 3.68 ml min-1 x kg. A major fraction of the dose (63.7 per cent) was excreted in urine over a 24-h collection period. Following intramuscular drug administration, the absorption half-life (t(1/2(a)), 5.3 min), MAT (17.1 min), C(max) (70.37 μg ml-1) and t(max) (15.9 min) indicate that the drug was rapidly absorbed. Systemic availability was 83.43 per cent after oral drug administration, absorption was preceded by a lag time (23.2 min). The t(1/2(a)) (41.5 min), MAT (81.6 min), C(max) (4.30 μg ml-1) and T(max) (90.6 min) indicate somewhat delayed absorption. Systemic availability (11.38 per cent) and the fraction of dose excreted unchanged in the urine (9.3 per cent) show that the drug was poorly absorbed. The apparent half-life (58.0 min) and MRT (137.6 min) following oral administration were significantly longer (p < 0.05) than following intravenous or intramuscular suggesting that the rate of absorption from the gastrointestinal tract decreases the elimination rate of the drug. In conclusion, HI-6 has limited distribution within the body, is rapidly eliminated mainly by renal excretion unchanged in the urine, and the bioavailability (i.e. rate and extent of absorption) of the drug varies with the route of administration.

UR - http://www.scopus.com/inward/record.url?scp=0027389027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027389027&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 93

EP - 105

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 2

ER -